Friday, July 10, 2026

Drug profile · INN

imipramine pamoate

imipramine pamoate (IMIPRAMINE PAMOATE) is a norepinephrine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — imipramine pamoate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

imipramine pamoate (IMIPRAMINE PAMOATE) is a norepinephrine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN imipramine pamoate
Brand IMIPRAMINE PAMOATE
Mechanism Norepinephrine transporter inhibitor
Target Sodium-dependent noradrenaline transporter
Route ORAL
Formulation CAPSULE

Mechanism of action

Norepinephrine transporter inhibitor

Primary target: Sodium-dependent noradrenaline transporter

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. amitriptyline hydrochloride Norepinephrine transporter inhibitor
  2. atomoxetine hydrochloride Norepinephrine transporter inhibitor
  3. desipramine hydrochloride Norepinephrine transporter inhibitor
  4. desvenlafaxine fumarate Norepinephrine transporter inhibitor
  5. doxepin hydrochloride Norepinephrine transporter inhibitor
  6. duloxetine hydrochloride Norepinephrine transporter inhibitor

Frequently asked questions

What is imipramine pamoate?

imipramine pamoate (IMIPRAMINE PAMOATE) is a norepinephrine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for imipramine pamoate?

IMIPRAMINE PAMOATE is a marketed brand name for imipramine pamoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of imipramine pamoate?

imipramine pamoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.